Connect with us

Science

NASA JPL team hopes to give greenhouse gas-monitoring satellite 'unprecedented' vision

Published

on

NASA JPL team hopes to give greenhouse gas-monitoring satellite 'unprecedented' vision

It was almost 10 years ago when Andrew Thorpe received a text from the crew flying overhead in a small aircraft: They had spotted a new methane hot spot.

Thorpe drove along winding dirt and mountain roads in an unwieldy rental SUV near the Four Corners region of the southwestern U.S. When he arrived at the spot relayed from the plane, he pulled out a thermal camera to scan for the plume. Sure enough, methane was seeping out of the ground, likely from a pipeline leak.

He found a marker sticking out of the desert with the phone number for a gas company, so he gave them a call. “I had the most confused individual on the other side of the phone,” Thorpe said. “I was trying to explain to them why I was calling, but this was back many years ago when there really weren’t any technologies that could do this.”

Over the years, the work has gotten Thorpe some unwanted attention. “I did some driving surveys in California .… A rent-a-cop was very suspicious of me and tried to scare me off,” said Thorpe. “If you set up a thermal camera on a public road and you’re pointing it at a tank beyond the fence, people are going to get nervous. I’ve been heckled by some oil and gas workers, but that’s par for the course.”

Today, Thorpe is part of a group that is at the forefront of greenhouse gas monitoring at NASA’s Jet Propulsion Laboratory in La Cañada Flintridge. For over 40 years, the Microdevices Laboratory at JPL has developed specialized instruments to measure methane and carbon dioxide with extreme precision.

Advertisement

The instruments, called spectrometers, detect gases based on which colors of sunlight they absorb. Earlier this year, a team of researchers from JPL, Caltech and research nonprofit Carnegie Science was selected as a finalist for a NASA award to put the technology into orbit.

JPL technicians work on an Airborne Visible/Infrared Imaging Spectrometer, or AVIRIS, that will be installed in an airplane to search for methane and other greenhouse gases.

(Myung J. Chun/Los Angeles Times)

If chosen for the satellite mission, the team’s carbon investigation, called Carbon-I, would launch in the early 2030s. Over the course of three years, Carbon-I would continuously map greenhouse gas emissions around the globe and take daily snapshots of areas of interest, allowing scientists to identify sources of climate pollution, such as power plants, pipeline leaks, farms and landfills.

Advertisement

While there are already multiple satellites monitoring these gases, Carbon-I’s resolution is unprecedented and would eliminate any guesswork in determining where the gas was emitted. “There’s no denying it anymore — once we see a plume, there’s no other potential source,” said Christian Frankenberg, co-principal investigator for Carbon-I and a professor of environmental science and engineering at Caltech.

Caltech professor Christian Frankenberg peers into the AVIRIS-5.

Caltech professor Christian Frankenberg, co-principal investigator for the proposed space-based Carbon-I emission-monitoring system, peers into an AVIRIS monitor under construction in a JPL lab.

(Myung J. Chun/Los Angeles Times)

Carbon-I’s finest, 100-foot resolution “is a very high resolution from space. That’s an incredible resolution to be able to get,” said Debra Wunch, a professor at the University of Toronto who studies Earth’s carbon cycle and is not involved in the Carbon-I proposal. “It would be able to give us much more insight into exactly the source of emissions .… This would be groundbreaking. You would be able to see individual stacks, individual parts of landfills, even.”

Historically, monitoring the release of greenhouse gases from individual emitters has been challenging — both carbon dioxide and methane are colorless and odorless. So scientists have often had to rely on adding up self-reported values from companies and estimates from research. For example, to estimate the amount of methane cows produce, scientists would have to determine how much methane one cow releases and multiply it by the total number of cows on Earth.

Advertisement

“If you look at international policies … currently they’re all based on these bottom-up inventories,” said Anna Michalak, co-principal investigator for Carbon-I and the founding director of the Carnegie Climate and Resilience Hub at Carnegie Science. “We need to get to a point where … we actually have an independent way of tracking what the emissions are.”

Carbon-I’s resolution will also give scientists new access to the atmosphere of the tropics, where clouds currently obscure most forms of satellite surveillance. “It’s their Achilles’ heel,” said Frankenberg.

Since tropical and subtropical forests absorb roughly a quarter of the CO2 humanity produces by burning fossil fuels, accurate data from this region of the globe is badly needed.

Satellites currently orbiting Earth with lower resolution can’t see through small gaps in the cloud coverage. They only see a blurred average of the cloudy and clear spots in the sky for each pixel. Carbon-I, with each pixel’s area almost 50 times smaller than that of most other satellites, can see the clearings and take measurements through them. In an April 2024 paper, Frankenberg, Michalak and their collaborators estimated that Carbon-I would be able to see past the clouds in the tropics anywhere from 10 to 100 times more frequently than its predecessors.

Carbon-I “is going to see things where people don’t know what’s going on,” said Thorpe, who has moved on from his graduate school days pointing thermal cameras at gas leaks and now works as a research technologist with the Microdevices Laboratory. “It’s going to open a whole new realm of science.”

Advertisement

JPL’s airborne greenhouse gas-monitoring program goes back decades, but the field of space monitoring is still fairly new. Near the start of 2016, NASA headquarters contacted the JPL team. There was an ongoing massive blowout at the Aliso Canyon gas storage facility near Porter Ranch, and NASA wanted the team to check it out.

The team flew over the site in a variant of a 1960s-era spy plane on three days over the course of a month while the Southern California Gas Co. fought to contain the blowout. At the same time, NASA’s Goddard Flight Center in Maryland pointed the NASA Earth Observing spacecraft’s Hyperion spectrometer at the leak.

Hyperion was designed to make observations of the Earth’s surface and filter out noise from the atmosphere. Now, they were trying to observe the atmosphere and filter out the surface, and for the first time, scientists observed a human-made point source of methane from orbit.

“The Hyperion result was pretty noisy, but you could still see the plume,” said Thorpe. “This was really a proof of concept that we could do it from space.”

Even if Carbon-I launches, it doesn’t mean the team will stop putting instruments on planes. From aircraft, the team is able to monitor areas of interest in even sharper resolution and for consecutive days at a time. Right now, a leaner, meaner version of the spectrometers that observed the Four Corners leak and Aliso Canyon blowout is flying a series of missions to monitor the emissions of offshore oil rigs in the Gulf of Mexico.

Advertisement
A twin-propeller King Air airplane in a hangar.

The twin-engine King Air plane used by JPL to conduct greenhouse gas-monitoring flights in its hangar at Hollywood Burbank Airport.

(Noah Haggerty/Los Angeles Times)

Plane missions also give the team an opportunity to try out new and improve spectrometers. “You can fix them, and you can upgrade them,” said JPL engineer Michael Eastwood, who’s worked with the spectrometers for over three decades and regularly flies with them. “You can take more risks, as opposed to spacecraft that need really mature, really well-known, high reliability — we’re not constrained like that.”

The air team is nimble, too. Typically, two crew members sit in the second row of a King Air twin-propeller aircraft looking at a stack of laptops and instruments with enough buttons to rival the plane’s cockpit. On the screens, they can look at real-time GPS data and spectrometer results and coordinate a flight plan with the pilots. The spectrometer — called AVIRIS, short for Airborne Visible/Infrared Imaging Spectrometer — sits in the third row, looking down through a window cut out in the floor.

The NASA program for which Carbon-I was selected as a finalist aims to fund space-based Earth science that will benefit society. The team was awarded $5 million to sharpen its project proposal before a final NASA review in 2025. There are three other finalists, and two will be selected for the launch.

Advertisement

This two-step process for selecting missions is new for NASA’s Earth science programs and requires JPL to compete with the rest of the scientific community, independent of their association with the space agency.

“If we’re talking about grocery money, [$5 million] seems like a lot of money, but it’s really a bargain,” said Michalak. “If you think about the fact that you’re committing $300 million toward a mission, spending 1.5% of that to really make sure it’s going to be fabulous and successful is extremely smart.”

In the meantime, the Carbon-I team is focused on showing NASA that it has the technical know-how to execute the project on time and under budget.

“I think all four of the missions in the current phase are absolutely worthwhile scientific missions,” said Michalak, “and 50% odds are not bad odds for a satellite mission.”

Advertisement

Science

What’s in a Name? For These Snails, Legal Protection

Published

on

What’s in a Name? For These Snails, Legal Protection

The sun had barely risen over the Pacific Ocean when a small motorboat carrying a team of Indigenous artisans and Mexican biologists dropped anchor in a rocky cove near Bahías de Huatulco.

Mauro Habacuc Avendaño Luis, one of the craftsmen, was the first to wade to shore. With an agility belying his age, he struck out over the boulders exposed by low tide. Crouching on a slippery ledge pounded by surf, he reached inside a crevice between two rocks. There, lodged among the urchins, was a snail with a knobby gray shell the size of a walnut. The sight might not dazzle tourists who travel here to see humpback whales, but for Mr. Avendaño, 85, these drab little mollusks represent a way of life.

Marine snails in the genus Plicopurpura are sacred to the Mixtec people of Pinotepa de Don Luis, a small town in southwestern Oaxaca. Men like Mr. Avendaño have been sustainably “milking” them for radiant purple dye for at least 1,500 years. The color suffuses Mixtec textiles and spiritual beliefs. Called tixinda, it symbolizes fertility and death, as well as mythic ties between lunar cycles, women and the sea.

The future of these traditions — and the fate of the snails — are uncertain. The mollusks are subject to intense poaching pressure despite federal protections intended to protect them. Fishermen break them (and the other mollusks they eat) open and sell the meat to local restaurants. Tourists who comb the beaches pluck snails off the rocks and toss them aside.

A severe earthquake in 2020 thrust formerly submerged parts of their habitat above sea level, fatally tossing other mollusks in the snail’s food web to the air, and making once inaccessible places more available to poachers.

Advertisement

Decades ago, dense clusters of snails the size of doorknobs were easy to find, according to Mr. Avendaño. “Full of snails,” he said, sweeping a calloused, violet-stained hand across the coves. Now, most of the snails he finds are small, just over an inch, and yield only a few milliliters of dye.

Continue Reading

Science

Video: This Parrot Has No Beak, But Is at the Top of the Pecking Order

Published

on

Video: This Parrot Has No Beak, But Is at the Top of the Pecking Order

new video loaded: This Parrot Has No Beak, But Is at the Top of the Pecking Order

Bruce, a disabled kea parrot, is missing his top beak. The bird uses tools to keep himself healthy and developed a jousting technique that has made him the alpha male of his group.

By Meg Felling and Carl Zimmer

April 20, 2026

Continue Reading

Science

Contributor: Focus on the real causes of the shortage in hormone treatments

Published

on

Contributor: Focus on the real causes of the shortage in hormone treatments

For months now, menopausal women across the U.S. have been unable to fill prescriptions for the estradiol patch, a long-established and safe hormone treatment. The news media has whipped up a frenzy over this scarcity, warning of a long-lasting nationwide shortage. The problem is real — but the explanations in the media coverage miss the mark. Real solutions depend on an accurate understanding of the causes.

Reporters, pharmaceutical companies and even some doctors have blamed women for causing the shortage, saying they were inspired by a “menopause moment” that has driven unprecedented demand. Such framing does a dangerous disservice to essential health advocacy.

In this narrative, there has been unprecedented demand, and it is explained in part by the Food and Drug Administration’s recent removal of the “black-box warning” from estradiol patches’ packaging. That inaccurate (and, quite frankly, terrifying) label had been required since a 2002 announcement overstated the link between certain menopause hormone treatments and breast cancer. Right-sizing and rewording the warning was long overdue. But the trouble with this narrative is that even after the black-box warning was removed, there has not been unprecedented demand.

Around 40% of menopausal women were prescribed hormone treatments in some form before the 2002 announcement. Use plummeted in its aftermath, dipping to less than 5% in 2020 and just 1.8% in 2024. According to the most recent data, the number has now settled back at the 5% mark. Unprecedented? Hardly. Modest at best.

Nor is estradiol a new or complex drug; the patch formulation has existed for decades, and generic versions are widely manufactured. There is no exotic ingredient, no rare supply chain dependency, no fluke that explains why women are suddenly being told their pharmacy is out of stock month after month.

Advertisement

The story is far more an indictment of the broken insurance industry: market concentration, perverse incentives and the consequences of allowing insurance companies to own the pharmacy benefit managers that effectively control drug access for the majority of users. Three companies — CVS Caremark, Express Scripts and OptumRx — manage 79% of all prescription drug claims in the United States. Those companies are wholly owned subsidiaries of three insurance behemoths: CVS Health, Cigna and UnitedHealth Group, respectively. This means that the same corporation that sells you your insurance plan also decides which drugs get covered, at what price, and whether your pharmacy can stock them. This is called vertical integration. In another era, we might have called it a cartel. The resulting problems are not unique to hormone treatments; they have affected widely used medications including blood thinners, inhalers and antibiotics. When a low-cost generic such as estradiol — a medication with no blockbuster profit margins and no patent protection — runs into friction in this system, the friction is not random. It is structural. Every decision in that chain is filtered through the same corporate profit motive. And when the drug in question is an off-patent estradiol patch that has negligible profit margins because of generic competition but requires logistical investment to keep consistently in stock? The math on “how much does this company care about ensuring access” is not complicated.

Unfortunately, there is little financial incentive to ensure smooth, consistent access. There is, however, significant financial incentive to steer patients toward branded alternatives, or simply to let supply tighten — because the companies aren’t losing much profit if sales of that product dwindle. This is not a conspiracy theory: The Federal Trade Commission noted this dynamic in a report that documented how pharmacy benefit managers’ practices inflate costs, reduce competition and harm patient access, particularly for independent pharmacies and for generic drugs.

Any claim that the estradiol patch shortage is meaningfully caused by more women now demanding hormone treatments is a distraction. It is also misogyny, pure and simple, to imply that the solution to the shortage is for women’s health advocates to dial it down and for women to temper their expectations. The scarcity of estradiol patches is the outcome of a broken system refusing to provide adequate supply.

Meanwhile, there are a few strategies to cope.

  • Ask your prescriber about alternatives. Estradiol is available in multiple formulations, including gel, spray, cream, oral tablet, vaginal ring and weekly transdermal patch, which is a different product from the twice-weekly patch and may be more consistently available depending on manufacturer and region.
  • Consider an online pharmacy. Many are doing a good job locating and filling these prescriptions from outside the pharmacy benefit manager system.
  • Call ahead. Patch shortages are inconsistent across regions and distributors. A call to pharmacies in your area, or a broader geographic radius if you’re able, can locate stock that your regular pharmacy doesn’t have.
  • Consider a compounding pharmacy. These sources can sometimes meet needs when commercially manufactured products are inaccessible. The hormones used are the same FDA-regulated bulk ingredients.

Beyond those Band-Aid solutions, more Americans need to fight for systemic change. The FTC report exists because Congress asked for it and committed to legislation that will address at least some of the problems. The FDA took action to change the labeling on estrogen in the face of citizen and medical experts’ pressure; it should do more now to demand transparency from patch manufacturers.

Most importantly, it is on all of us to call out the cracks in the current system. Instead of repeating “there’s a patch shortage” or a “surge in demand,” say that a shockingly small minority of menopausal women still even get hormonal treatments prescribed at all, and three drug companies control the vast majority of claims in this country. Those are the real problems that need real solutions.

Advertisement

Jennifer Weiss-Wolf, the executive director of the Birnbaum Women’s Leadership Center at New York University School of Law, is the author of the forthcoming book When in Menopause: A User’s Manual & Citizen’s Guide. Suzanne Gilberg, an obstetrician and gynecologist in Los Angeles, is the author of “Menopause Bootcamp.”

Continue Reading
Advertisement

Trending